Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Apomorphine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 4/20 | 0.97 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.97 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.98 |
| ▸ | HPGD | P15428 | 6/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.98 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.98 |
| ▸ | MAPT | P10636 | 5/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.98 |
| ▸ | PKM | P14618 | 4/20 | 0.98 |
| ▸ | TP53 | P04637 | 4/20 | 0.98 |
| ▸ | LMNA | P02545 | 4/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.98 |
| ▸ | GAA | P10253 | 3/20 | 0.98 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.98 |
| ▸ | G6PD | P11413 | 2/20 | 0.98 |
| ▸ | MPI | P34949 | 2/20 | 0.98 |
| ▸ | HTT | P42858 | 2/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apomorphine SCHEMBL21846961 | 0.99 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPK1 | |
| Apomorphine SCHEMBL4755216 | 0.99 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPK1 | |
| Apomorphine SCHEMBL29565637 | 0.99 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPK1 | |
| Apomorphine SCHEMBL1321033 | 0.99 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPK1 | |
| Apomorphine SCHEMBL5429071 | 0.99 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPK1 | |
| Apomorphine SCHEMBL232473 | 0.99 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPK1 | |
| Apomorphine SCHEMBL30395698 | 0.99 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPK1 | |
| Apomorphine SCHEMBL21410343 | 0.99 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPK1 | |
| Apomorphine SCHEMBL8541 | 0.99 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPK1 | |
| Apomorphine SCHEMBL5605456 | 0.99 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023172649-A9 | APOMORPHINE HYDROCHLORIDE TRIMETHANOLATE, ITS POLYMORPHS AND ITS USES | ALEXZA PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023172649-A1 | APOMORPHINE HYDROCHLORIDE TRIMETHANOLATE, ITS POLYMORPHS AND ITS USES | ALEXZA PHARMACEUTICALS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| CN-107548388-A | Crystal habit of apomorphine and application thereof | 纽罗德姆有限公司 | 2018-01-05 | — | — | CN | disclosed |
| US-20170368052-A1 | CRYSTAL FORMS OF APOMORPHINE AND USES THEREOF | NEURODERM, LTD. (IL) | 2017-12-28 | — | — | US | disclosed |
| EP-3237386-A2 | CRYSTAL FORMS OF APOMORPHINE AND USES THEREOF | Neuroderm Ltd (IL) | 2017-11-01 | — | — | EP | disclosed |
| WO-2016103262-A2 | CRYSTAL FORMS OF APOMORPHINE AND USES THEREOF | NEURODERM LTD (IL) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170368052-A1 | CRYSTAL FORMS OF APOMORPHINE AND USES THEREOF | PARK7, SNCA, SLC6A3 | DRD2 372/4885DRD4 553/4885DRD3 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.